In this video, Juan Carlos Cardet, MD, of the University of South Florida (USF) Health Morsani College of Medicine in Tampa, ...

AstraZeneca’s Fasenra (benralizumab) has seen its fortunes reverse after NICE approved the drug for severe eosinophilic asthma – broadening its recommendations for the drug’s use and giving ...

That gives it an advantage over other biologics for severe asthma, such as Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's IL-5 inhibitor Fasenra (benralizumab) - which ...

Principal treatment-related toxicities that come from amivantamab administration include skin-related reactions, higher risk of venous thrombolism, and infusion-related reactions.

The GloBodies are bound by benralizumab-specific ADA in plasma/serum and complexes are captured by immobilized protein G and quantitated using luminometry, following the addition of nanoluciferase ...